Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Memory-like natural killer cells for cancer immunotherapy53
Iron metabolism in infections: Focus on COVID-1950
Toward a pathophysiology inspired treatment of VEXAS syndrome43
Epidemiology of VITT34
Aplastic anemia: Pathophysiology33
Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)32
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome32
Platelet-activating anti-PF4 disorders: An overview30
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)29
Thrombotic manifestations of VEXAS syndrome28
Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization25
Genetics of somatic auto-inflammatory disorders24
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?23
VEXAS within the spectrum of rheumatologic disease22
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement21
Modulating NK cell metabolism for cancer immunotherapy20
Shaping the bone through iron and iron-related proteins18
Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity17
20 years of Hepcidin: How far we have come17
VEXAS syndrome: An inflammatory and hematologic disease15
Laboratory testing for VITT antibodies13
Improving CAR T-cells: The next generation13
Longitudinal Aspects of VITT11
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease11
Natural killer cell engineering – a new hope for cancer immunotherapy11
Pharmacogenomics and ALL treatment: How to optimize therapy10
Applications of virus-specific T cell therapies post-BMT10
TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics10
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients10
NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles10
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multipl9
Immunosuppressive therapy in severe aplastic anemia9
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation9
Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome9
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria9
Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity8
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome7
Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 20207
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies7
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management7
The epidemiology of Waldenström macroglobulinemia7
Epidemiology and etiology of diffuse large B-cell lymphoma7
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia7
Place of care manufacturing of chimeric antigen receptor cells: Opportunities and challenges7
The role of viruses in HIV-associated lymphomas7
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress7
0.12086296081543